FR0010259150
© Globe Newswire
09.12.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 49- 2025
News Preview
Attachment...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
IPN
LISTED
EURONEXT
Ipsen - November 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
IPN
LISTED
EURONEXT
Ipsen provides update on legacy of Henri Beaufour
News Preview
PARIS, FRANCE, 5 December 2025, Ipsen (Euronext: IPN; ADR: IPSEY) has been informed that the shares of Beech Tree will be transferred to the Alasol Foundation, in accordance with the wishes of Mr. Henri Beaufour, Ipsen’s Board Member and a representative of the founding family who passed away on November 28, 2025. This transfer is expected to take...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
02.12.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 48 - 2025
News Preview
Attachment...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
01.12.2025
IPN
LISTED
EURONEXT
Ipsen mourns the passing of Henri Beaufour, a founding family Board member
News Preview
PARIS, FRANCE, 1 DECEMBER 2025 - It is with great sadness that Ipsen (Euronext: IPN; ADR: IPSEY) today announces that Henri Beaufour, Ipsen Board Member and a representative of the founding family, passed away on Friday, 28 November 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
25.11.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 47 - 2025
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.11.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 46 - 2025
News Preview
Attachment...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 45 - 2025
News Preview
Attachment...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2025
IPN
LISTED
EURONEXT
Ipsen - October 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2025
IPN
LISTED
EURONEXT
Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue
News Preview
Paris, France – 7 November, 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new Primary Biliary Cholangitis (PBC) data with IQIRVO® from the ELATIVE trial1, 2 will be presented in two late-breaking sessions, at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD). ...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 44 - 2025
News Preview
Attachment...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.10.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 43 - 2025
News Preview
Attachment...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
22.10.2025
IPN
LISTED
EURONEXT
Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
News Preview
PARIS, FRANCE, 22 October 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the year to date and the third quarter of 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
22.10.2025
IPN
LISTED
EURONEXT
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
News Preview
PARIS AND MARSEILLE, FRANCE, 22 October 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) and ImCheck Therapeutics today announced they have entered into a definitive share purchase agreement in which Ipsen will acquire all issued and outstanding shares of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncolog...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.10.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 42 - 2025
News Preview
Attachment...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.10.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 41 - 2025
News Preview
Attachment...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 40 - 2025
News Preview
Attachment...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
IPN
LISTED
EURONEXT
Ipsen - September 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.09.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2025
News Preview
Attachment...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.09.2025
IPN
LISTED
EURONEXT
Ipsen et BioLabs Hôtel-Dieu décernent le Golden Ticket Ipsen 2025 à DETERA Therapeutics
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2025
News Preview
Attachment...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
IPN
LISTED
EURONEXT
Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
News Preview
PARIS, FRANCE, 22 September 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first aesthetic data (n=183) for glabellar lines with internally developed IPN10200, following Stage 1 of the multi-stage, ongoing Phase II LANTIC trial. Patients treated with IPN10200 showed a statistically significant improvement in response at Week 4 vs plac...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
IPN
LISTED
EURONEXT
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC
News Preview
Paris, France – 19 September 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval for Bylvay® (odevixibat) for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC). PFIC is a group of rare genetic disorders in whi...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2025
News Preview
Attachment...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.09.2025
IPN
LISTED
EURONEXT
Ipsen - August 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.09.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 36 - 2025
News Preview
Attachment...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2025
News Preview
Aggregated presentation by day and by market Statement of transactions in own shares from August 25th to August 29th 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.08.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2025
News Preview
Aggregated presentation by day and by market Statement of transactions in own shares from August 18th to August 22nd 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.08.2025
IPN
LISTED
EURONEXT
Ipsen - July 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.08.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 2025
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.08.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2025
News Preview
Attachment...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.07.2025
IPN
LISTED
EURONEXT
Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)
News Preview
Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.07.2025
IPN
LISTED
EURONEXT
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
News Preview
PARIS, FRANCE, 31 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-carebiopharmaceutical company, today presents its financial results for the first half of 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.07.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2025
News Preview
Attachment...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.07.2025
IPN
LISTED
EURONEXT
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
News Preview
PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.07.2025
IPN
LISTED
EURONEXT
Ipsen announces changes to its Executive Committee
News Preview
PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee:...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.07.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2025
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.07.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2025
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.07.2025
IPN
LISTED
EURONEXT
Ipsen - June 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.07.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 27- 2025
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.07.2025
IPN
LISTED
EURONEXT
Ipsen - Half year statement - 2025 06 30
News Preview
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2025
IPN
LISTED
EURONEXT
Ipsen inaugure son nouveau siège social mondial à Paris, en présence du ministre délégué chargé de la Santé et de l'Accès aux Soins Yannick Neuder
News Preview
PARIS, FRANCE, 2 JUILLET 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) inaugure aujourd’hui son nouveau siège social dans le 15ème arrondissement de Paris au 70, rue Balard. Le bâtiment, entièrement rénové pour accueillir le siège mondial d’Ipsen, s’étend sur une superficie totale de 9 500 m² répartis sur 7 étages (hors rez-de-chaussée) et accueille 600...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2025
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.06.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2025
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.06.2025
IPN
LISTED
EURONEXT
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
News Preview
PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancrea...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.06.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2025
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.06.2025
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2025
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.06.2025
IPN
LISTED
EURONEXT
Ipsen - May 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
IPN
LISTED
EURONEXT
PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer
News Preview
BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Exe...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.06.2025
IPN
LISTED
EURONEXT
Ipsen S.A. - Initiation of the share buy-back program
News Preview
Regulated information...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.05.2025
IPN
LISTED
EURONEXT
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
News Preview
PARIS, France, 31 May 2025 – Late-breaking (LBA4175) post-hoc analysis data from the Phase III NAPOLI 3 study were presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These results found a median overall survival (mOS) of 19.5 months among long-term survivors (n=15) with metastatic pancreatic adenocarcinoma (mPD...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2025
IPN
LISTED
EURONEXT
Ipsen S.A. - Annual General Meeting held on 21 May 2025
News Preview
Annual General Meeting of Ipsen S.A. held on 21 May 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.05.2025
IPN
LISTED
EURONEXT
Ipsen - April 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2025
IPN
LISTED
EURONEXT
Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis
News Preview
PARIS, FRANCE, 7 May 2025 Today, Ipsen (Euronext: IPN; ADR: IPSEY) announced new data from two late-breaking presentations on IQIRVO® (elafibranor) during the European Association for the Study of the Liver congress....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.04.2025
IPN
LISTED
EURONEXT
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting
News Preview
Information relating to the holding of the Combined Shareholders’ Meeting of 21 May 2025 of Ipsen S.A....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.04.2025
IPN
LISTED
EURONEXT
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
News Preview
PARIS, FRANCE, 24 April 2025 Ipsen (Euronext: IPN; ADR: IPSEY) will be presenting data from the late-breaking abstract on elafibranor in the investigational Phase II ELMWOOD study at the European Association for the Study of the Liver (EASL) congress as an oral presentation, on 10 May at 11.15 CET. For the first time data highlighting the potential...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.04.2025
IPN
LISTED
EURONEXT
Correction: Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l’exercice 2025
News Preview
ERRATUM – ANNULE ET REMPLACE...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.04.2025
IPN
LISTED
EURONEXT
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
News Preview
PARIS, FRANCE, 16 April 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents sales for the first quarter of 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
14.04.2025
IPN
LISTED
EURONEXT
Ipsen - March 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.04.2025
IPN
LISTED
EURONEXT
Ipsen publishes its 2024 Universal Registration Document
News Preview
Ipsen publishes its 2024 Universal Registration Document...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
